These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33320635)

  • 1. Bioengineered
    Chakraborty J; Banerjee I; Vaishya R; Ghosh S
    ACS Biomater Sci Eng; 2020 Dec; 6(12):6540-6555. PubMed ID: 33320635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks.
    Tatara AM
    Tissue Eng Part A; 2020 May; 26(9-10):468-474. PubMed ID: 32272857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D culture models to study SARS-CoV-2 infectivity and antiviral candidates: From spheroids to bioprinting.
    de Melo BAG; Benincasa JC; Cruz EM; Maricato JT; Porcionatto MA
    Biomed J; 2021 Mar; 44(1):31-42. PubMed ID: 33602633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D Lung Tissue Models for Studies on SARS-CoV-2 Pathophysiology and Therapeutics.
    Plebani R; Bai H; Si L; Li J; Zhang C; Romano M
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spheroids and organoids as humanized 3D scaffold-free engineered tissues for SARS-CoV-2 viral infection and drug screening.
    Kronemberger GS; Carneiro FA; Rezende DF; Baptista LS
    Artif Organs; 2021 Jun; 45(6):548-558. PubMed ID: 33264436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism.
    Policard M; Jain S; Rego S; Dakshanamurthy S
    Virus Res; 2021 Aug; 301():198464. PubMed ID: 34058265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines.
    Awadasseid A; Wu Y; Tanaka Y; Zhang W
    Biomed Pharmacother; 2021 May; 137():111330. PubMed ID: 33550043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging nanotechnology role in the development of innovative solutions against COVID-19 pandemic.
    Bhutta ZA; Kanwal A; Ali M; Kulyar MF; Yao W; Shoaib M; Ashar A; Mahfooz A; Ijaz M; Ijaz N; Asif M; Nawaz S; Mahfooz MR; Kanwal T
    Nanotechnology; 2021 Sep; 32(48):. PubMed ID: 34320471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pandemic COVID-19 caused by SARS-CoV-2: genetic structure, vaccination, and therapeutic approaches.
    Marei HE; Althani A; Afifi N; Pozzoli G; Caceci T; Angelini F; Cenciarelli C
    Mol Biol Rep; 2021 Sep; 48(9):6513-6524. PubMed ID: 34398427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Organoids and Organs-on-Chips for Addressing COVID-19 Challenges.
    Wang Y; Wang P; Qin J
    Adv Sci (Weinh); 2022 Apr; 9(10):e2105187. PubMed ID: 35107217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Insight into Immunopathology of SARS-CoV-2 Infection.
    Soni B; Kabra R; Singh S
    J Interferon Cytokine Res; 2021 Jul; 41(7):244-257. PubMed ID: 34280026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stopping pandemics before they start: Lessons learned from SARS-CoV-2.
    Edwards AM; Baric RS; Saphire EO; Ulmer JB
    Science; 2022 Mar; 375(6585):1133-1139. PubMed ID: 35271333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects.
    Zheng J; Deng Y; Zhao Z; Mao B; Lu M; Lin Y; Huang A
    Cell Mol Immunol; 2022 Feb; 19(2):150-157. PubMed ID: 34645940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies.
    Zabidi NZ; Liew HL; Farouk IA; Puniyamurti A; Yip AJW; Wijesinghe VN; Low ZY; Tang JW; Chow VTK; Lal SK
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primed for global coronavirus pandemic: Emerging research and clinical outcome.
    Ahamad S; Branch S; Harrelson S; Hussain MK; Saquib M; Khan S
    Eur J Med Chem; 2021 Jan; 209():112862. PubMed ID: 33070079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome.
    Borges RC; Hohmann MS; Borghi SM
    Int Rev Immunol; 2021; 40(1-2):108-125. PubMed ID: 33191813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D Bioprinting for fabrication of tissue models of COVID-19 infection.
    Kabir A; Datta P; Oh J; Williams A; Ozbolat V; Unutmaz D; T Ozbolat I
    Essays Biochem; 2021 Aug; 65(3):503-518. PubMed ID: 34028514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.